Chiaki Kawanishi

Chiaki Kawanishi

Auto-generated profile, based on publicly available information

Chiaki Kawanishi

Department of Neuropsychiatry, Sapporo Medical University Graduate School of Medicine, S1, W17, Chuo-ku, Sapporo 060-8556, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in The Lancet Psychiatry
Verified
Journal Article
Closed access
CKChiaki Kawanishi
Chiaki Kawanishi
TATohru Aruga
Tohru Aruga
NINaoki Ishizuka
Naoki Ishizuka
NYNaohiro Yonemoto
Naohiro Yonemoto
KOKotaro Otsuka
Kotaro Otsuka
YHYoshio Hirayasu
Yoshio Hirayasu

14 November 2012 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
YIYohko Iwamoto
Yohko Iwamoto
CKChiaki Kawanishi
Chiaki Kawanishi
IKIkuko Kishida
Ikuko Kishida
TFTaku Furuno
Taku Furuno
MFMami Fujibayashi
Mami Fujibayashi
YHYoshio Hirayasu
Yoshio Hirayasu
Background: Antipsychotic drugs are considered a trigger factor for autonomic dysregulation, which has been shown to predict potentially fatal arrhythmias in schizophrenia. However, the dose-dependent effect of antipsychotic drugs and other psychotropic drugs on autonomic nervous system (ANS) activity remain unclear. The purpose of this study was to investigate the dose-dependent effect of antipsychotic drugs and other clinical factors on ANS activity in an adequate sample size of patients with schizophrenia. Methods: A total of 211 Japanese patients with schizophrenia and 44 healthy subjects participated in this study. ANS activity was assessed by means of heart rate variability (HRV) power spectral analysis. Antipsychotic drug treatment and various clinical factors were investigated for each participant. The patient group was categorized into three subgroups according to daily dose of antipsychotic drug, and HRV was compared between groups. Results: The results showed significantly decreased low-frequency and high-frequency components of HRV in the patient group compared to the control group. The high-dose group showed a significantly lower HRV than the medium-dose group and an even lower HRV than the low-dose group. In addition, a significant association between HRV and antipsychotic drug dose was identified by multiple regression analysis. HRV was not associated with age, sex, body mass index, duration of illness, or daily dose of other psychotropic drugs. Conclusion: These results suggest that antipsychotic drugs exert a significant dose-dependent effect on the extent of decline in ANS activity, and that optimal antipsychotic medication is required to avoid possible cardiovascular adverse events in patients with schizophrenia.

19 September 2012 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
CDChiho Doihara
Chiho Doihara
CKChiaki Kawanishi
Chiaki Kawanishi
NONene Ohyama
Nene Ohyama
TYTomoki Yamada
Tomoki Yamada
MNMakiko Nakagawa
Makiko Nakagawa
YHYoshio Hirayasu
Yoshio Hirayasu
Suicide attempt is a risk factor for suicide. To investigate trait impulsivity among suicide attempters, 93 attempters admitted to an emergency department and 113 healthy controls were evaluated using the Japanese version of the Barratt Impulsiveness Scale (BIS‐11J). Impulsivity was analyzed in relation to clinical data in the attempters. Total BIS‐11J, attention impulsiveness, and motor impulsiveness scores were significantly higher in the attempters than in the controls. Both total BIS‐11J and non‐planning impulsiveness scores were significantly higher in attempters with schizophrenia and other psychotic disorders among the diagnostic groups. Control of impulsivity should be considered as one of the targets for suicide prevention.

12 March 2020 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
YKYoshitaka Kawashima
Yoshitaka Kawashima
NYNaohiro Yonemoto
Naohiro Yonemoto
CKChiaki Kawanishi
Chiaki Kawanishi
KOKotaro Otsuka
Kotaro Otsuka
MMMasaru Mimura
Masaru Mimura
MYMitsuhiko Yamada
Mitsuhiko Yamada

1 April 2017 in Psychiatry Research
Verified
Journal Article
Closed access
KIKeisuke Inoue
Keisuke Inoue
CKChiaki Kawanishi
Chiaki Kawanishi
KOKotaro Otsuka
Kotaro Otsuka
YCYoshinori Cho
Yoshinori Cho
MSMasaki Shiraishi
Masaki Shiraishi
YHYoshio Hirayasu
Yoshio Hirayasu

1 September 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
CKChiaki Kawanishi
Chiaki Kawanishi
TITakao Ishii
Takao Ishii
NYNaohiro Yonemoto
Naohiro Yonemoto
MYMitsuhiko Yamada
Mitsuhiko Yamada
HTHirokazu Tachikawa
Hirokazu Tachikawa
RYReiji Yoshimura
Reiji Yoshimura
Introduction Suicide attempt is the most important risk factor for later suicide. A randomised-controlled, multicentre trial of postsuicide attempt case management for the prevention of further suicide attempts in Japan, named ACTION-J, has established effective interventions for prevention of suicide reattempts. The ACTION-J assertive case management intervention programme was adopted by the Japanese Ministry of Health, Labour and Welfare in 2016, when medical fees were revised. This nationwide programme is provided to patients who attempt suicide and who are admitted to emergency departments in Japan. The aim of the present study is to examine the current implementation status of the ACTION-J programme. The present study also aims to clarify which patients’ and hospitals’ factors affect the implementation of the programme. Methods and analysis This is a prospective, multicentre, patient registry cohort study. Participants will be suicide attempters admitted to the emergency departments of medical facilities with both psychiatry and emergency departments. The assertive case management programme will be delivered to participants by a case manager for up to 24 weeks, based on psychiatric diagnoses, social risks and patient needs. The core feature of the programme is to encourage patients to participate in psychiatric treatment. The primary outcome will be the proportion of patients still participating in the case management intervention at 24 weeks after registration. The secondary outcomes will include measures of the fidelity of the case management intervention. The fidelity will be evaluated using a fidelity assessment manual developed by the study group. Ethics and dissemination This observational study has been approved by the ethics board of Sapporo Medical University. Enrolment began in October 2016 and will continue until December 2018. Dissemination plans include presentations at scientific conferences and scientific publications. Trial registration UMIN000024474.